Functional

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

Retrieved on: 
Dienstag, Juni 4, 2024
ENDO, Patient, Serum, Functional, Doctor of Philosophy, Clinical trial, Growth, GHD, M6, Endocrine Society, IQR, Political moderate, Functional principal component analysis, FPCA, Therapy, LUMO, FDA, Growth hormone, D1, Poster, Transgender hormone therapy, Pattern, AHV, Pulse

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) , held in Boston, MA, June 1-4, 2024.

Key Points: 
  • AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) , held in Boston, MA, June 1-4, 2024.
  • The posters were presented in parallel sessions on Monday June 3, 2024.
  • “The new analyses of data from our OraGrowtH212 Trial further characterized LUM-201’s unique ability to augment the natural pulsatile secretion of growth hormone, producing comparable growth to injectable rhGH with significantly less exposure to circulating growth hormone,” said John C. McKew, PhD, President and Chief Scientific Officer of Lumos Pharma.
  • At baseline GH secretion was 0.19 ±0.09 μg/kg/12-hrs; pulsatile GH was 1.17 ±0.66 μg/kg/12-hrs; and total GH was 1.35 ±0.66 μg/kg/12-hrs.

First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024

Retrieved on: 
Samstag, Juni 1, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Leukemia, Genomics, Biomarker, ASCO, Cancer, CLIA, Florida Department, Machine learning, Florida International University, Workflow, Patient, FIU, Nature Medicine, Community foundation, Data, DST, Clinical Laboratory, Society, Hospital, Ben Goertzel, First ascent, Drug development, Assistant, AI, Functional, FPM, Progression-free survival, Lung cancer, Survival, Cleveland Clinic, Partnership, Physician, NIMHD

First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat cancers.

Key Points: 
  • First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat cancers.
  • The study findings were presented during poster sessions at the 2024 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
  • Samples were taken from resections, core biopsies, and fine-needle biopsies from primary and metastatic lesions from pediatric and adult cancer patients.
  • First Ascent Biomedical’s Functional Medicine Platform (FPM) is a first-in-kind AI-driven drug prediction platform that integrates drug sensitivity testing of cancer cells with DNA/RNA sequencing.

Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference

Retrieved on: 
Montag, Mai 20, 2024
Lung, Patient, PAH, American Thoracic Society, Clinical trial, Orthostatic hypertension, Drug development, Conference, FRI, Pulmonary hypertension, ATS, Functional, RDA, Pharmaceutical industry

DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, today announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society (ATS) 2024 International Conference being held May 17-22, 2024, in San Diego, California.

Key Points: 
  • DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, today announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society (ATS) 2024 International Conference being held May 17-22, 2024, in San Diego, California.
  • These new data generated by FLUIDDA, Inc., using their proprietary Functional Respiratory Imaging (FRI) and Rapid Deposition Analysis (RDA) platforms, predicted efficient deposition of AER-901 throughout the lung in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) or pulmonary arterial hypertension (PAH), as well as healthy volunteers.
  • “We believe that these new modeling data, generated in collaboration with FLUIDDA, strongly highlight the differentiated AER-901 profile across multiple forms of pulmonary hypertension,” said Anne Whitaker, Chairwoman and Chief Executive Officer of Aerami.
  • As a novel approach, Aerami believes that the uniPHied design could provide a blueprint that may accelerate drug development for high unmet need in multiple forms of pulmonary hypertension.

Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference

Retrieved on: 
Mittwoch, Mai 8, 2024
DPI, Inhalation, ATS, Pulmonary hypertension, RDA, MD, PAH, Conference, Orthostatic hypertension, Functional, FRI, American Thoracic Society, Pharmaceutical industry

One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.

Key Points: 
  • One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.
  • These modeling data were generated by FLUIDDA, Inc., using their proprietary Functional Respiratory Imaging (FRI) And Rapid Deposition Analysis (RDA) platforms.
  • In addition, the unique and innovative design of the “uniPHied” platform Phase 2 trial will be presented, demonstrating the optionality to expeditiously evaluate AER-901 in multiple pulmonary hypertension cohorts (initially PH-ILD and PAH).
  • "We are excited to present new lung deposition modeling data that we believe strongly support the differentiation of AER-901 and its potential to reverse the vascular remodeling process central to multiple forms of pulmonary hypertension," said Gary Burgess, MD, Chief Medical Officer of Aerami.

Dr. Golberg Institute of Functional and Aesthetic Medicine Announces Partnership with Casa Cipriani

Retrieved on: 
Freitag, April 19, 2024
Relaxation, Rejuvenation, Intravenous therapy, Health, Partnership, Battery Maritime Building, Casa Cipriani, Functional, Patient, Medicine

New York, New York--(Newsfile Corp. - April 19, 2024) - New York City's medical and hospitality scenes unite as the esteemed Dr. Golberg Institute of Functional & Aesthetic Medicine unveils its partnership with Casa Cipriani.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 19, 2024) - New York City's medical and hospitality scenes unite as the esteemed Dr. Golberg Institute of Functional & Aesthetic Medicine unveils its partnership with Casa Cipriani.
  • With this partnership, Casa Cipriani members and hotel guests alike will have access to services such as custom IVs, medical concierge services, and non-surgical aesthetics.
  • The partnership with the Dr. Golberg Institute further solidifies Casa Cipriani's commitment to offering guests a complete wellness experience.
  • As the collaboration between the Dr. Golberg Institute of Functional & Aesthetic Medicine and Casa Cipriani takes shape, patients can look forward to a new level of luxury and sophistication in their healthcare journey.

LTIMindtree Collaborates with Vodafone to Deliver Connected, Smart IoT and Industry X.0 Solutions

Retrieved on: 
Donnerstag, April 18, 2024
Technology, Mobile, Wireless, Consulting, Telecommunications, Professional Services, Software, IOT (Internet of Things), Data Management, VoIP, Fourth Industrial Revolution, Internet, Internet of things, Machine learning, LTIMindtree, Partnership, Artificial intelligence, Small Business Saturday, Functional, Digital transformation, Growth, Customer service

Through this partnership, LTIMindtree will offer connected and smart IoT solutions, powered by its Insight NXT platform (iNXT) and Vodafone’s IoT Managed Connectivity, that will enable Industry X.0 and digital transformation across multiple vertical sectors.

Key Points: 
  • Through this partnership, LTIMindtree will offer connected and smart IoT solutions, powered by its Insight NXT platform (iNXT) and Vodafone’s IoT Managed Connectivity, that will enable Industry X.0 and digital transformation across multiple vertical sectors.
  • LTIMindtree’s iNXT Business Unit brings Technical and Functional components, and together with Vodafone’s IoT Managed Connectivity solutions it will deliver to solve complex business challenges.
  • By drawing on a best-in-class ecosystem of partners, LTIMindtree will empower clients to maximize their efforts across revenue acceleration through newer business models, cost efficiency and sustainability, leveraging Smart IoT and Industry X.0.
  • Gemma Barsby, UK Head of IoT, Vodafone, said, “Our partnership with LTIMindtree means Vodafone can support the real-time delivery of IoT managed services to their clients and empower them in driving cost efficiencies and greater productivity.

New Study Published on Specialty Enzymes & Probiotics' Powerhouse Probiotic SEBtilis™

Retrieved on: 
Donnerstag, April 25, 2024
Health, Pasteurization, Probiotic, Functional, Drink, Bacillus subtilis, Gastric acid, Research, Dietary supplement

The objective of the newly published study, titled "In-Depth Functional Characterization of Bacillus subtilis PLSSC Revealing its Robust Probiotic Attributes," was to evaluate the antimicrobial activity of Bacillus subtilis PLSSC and its ability to survive the harsh conditions of gastrointestinal digestion and industrial processing.

Key Points: 
  • The objective of the newly published study, titled "In-Depth Functional Characterization of Bacillus subtilis PLSSC Revealing its Robust Probiotic Attributes," was to evaluate the antimicrobial activity of Bacillus subtilis PLSSC and its ability to survive the harsh conditions of gastrointestinal digestion and industrial processing.
  • Bacillus subtilis PLSSC exhibited excellent resilience when exposed to gastric acid, bile stress, simulated gastrointestinal digestion and thermal exposure, (surviving pasteurization), maintaining viability ranging from 86.18% to 100%.
  • Another key highlight of the study was the characterization of Bacillus subtilis PLSSC's broad-spectrum antimicrobial activity.
  • Through its production of antimicrobial peptides, Bacillus subtilis PLSSC can support the inhibition of pathogenic growth.

Dr. Golberg Institute of Functional and Aesthetic Medicine Announces Dr. Alexander Golberg Awarded Top Aesthetic Doctor in 2024 Aesthetic Everything Awards

Retrieved on: 
Dienstag, März 19, 2024
Plastic surgery, Functional, Patient, Health, Research, Publication, Aesthetics, Medicine, Medical device

New York, New York--(Newsfile Corp. - March 19, 2024) - The Dr. Golberg Institute of Functional and Aesthetic Medicine proudly declares Dr. Alexander Golberg as the recipient of the title of Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards.

Key Points: 
  • New York, New York--(Newsfile Corp. - March 19, 2024) - The Dr. Golberg Institute of Functional and Aesthetic Medicine proudly declares Dr. Alexander Golberg as the recipient of the title of Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards.
  • The recognition as Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards reaffirms Dr. Golberg's position as a leading figure in the realm of aesthetic procedures.
  • At the Dr. Golberg Institute of Functional and Aesthetic Medicine, Dr. Alexander Golberg offers patients a comprehensive range of aesthetic treatments tailored to their individual needs.
  • With his dedication to innovation and patient care, Dr. Golberg contributes to the advancement of aesthetic medicine.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Retrieved on: 
Montag, April 1, 2024
Administration, Annual report, B cell, Obesity, Development, Cell, Patent, Library, Visual analogue scale, Patient, DSM-IV codes, Data monitoring committee, Form 10-K, Security (finance), Functional, Adipocyte, Type 2 diabetes, Small business, Investment, Research and development, NOA, European Patent Convention, Safety, Infrared spectroscopy correlation table, Orthopaedic Research Society, Annual general meeting, Pharmaceutical industry

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.

Key Points: 
  • MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov , and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • At December 31, 2023, BioRestorative had cash, cash equivalents and investments in marketable securities of $11.07 million.

TMS Health and Wellness Introduces Cutting-Edge Brain Scanning For Enhanced TMS Therapy Effectiveness

Retrieved on: 
Montag, April 8, 2024
Depression, Mindfulness, Magnetic resonance, Medicine, Health, Neuroimaging, Patient, TMS, Anxiety, Addiction, Chronic pain, Functional, Concierge medicine, Meditation, Wellness, Transcranial magnetic stimulation, Homeopathy, Neurofeedback, Map, Medical imaging

COSTA MESA, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- In a significant advancement for treating anxiety, depression, and other mental health conditions, TMS Health and Wellness proudly announces the integration of comprehensive brain scanning technology into its Transcranial Magnetic Stimulation (TMS) Therapy protocols. This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.

Key Points: 
  • This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.
  • By utilizing detailed brain imaging to map and understand each patient's unique neural patterns, TMS Health and Wellness can customize the application of TMS Therapy with greater precision than ever before.
  • The clinic's expanded services now include:
    With the introduction of brain scanning technology, TMS Health and Wellness reinforces its dedication to pioneering in the mental health space and its mission of treating the "whole person."
  • TMS Therapy enhanced with Full Brain Scans and Functional MRI is available now.